MAGEA2B: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

Target Name: MAGEA2B

NCBI ID: G266740

MAGEA2B

MAGEA2B: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

Cancer is a leading cause of morbidity and mortality worldwide, affecting millions of individuals worldwide. One of the most common types of cancer is breast cancer, which has a poor prognosis due to its high incidence and rapid progression. Therefore, there is a great need for new treatments and diagnostic tools to improve treatment outcomes.

One of the promising avenues for cancer research is the study of cancer antigens, which are molecules that cancer cells produce and that can be used as targets for cancer therapies. One such antigen is cancer/testis antigen 1.2 (MAGEA2B), which has been identified as a potential drug target and biomarker for cancer and testis antigens.

MAGEA2B: Structure and Function

MAGEA2B is a 120-kDa glycoprotein that is expressed in a variety of tissues, including cancer cells, fetal tissues, and normal tissues. It is composed of two heavy chains and two light chains that are held together by disulfide bonds. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region.

MAGEA2B is a self-antigen, which means that it can bind to itself and can also bind to antigens from the same species. This self-antigenity makes it a potential biomarker for cancer and testis antigens.

MAGEA2B has been shown to be expressed in a variety of tissues and has been used as a marker for cancer and testis antigens in various clinical trials. For example, a study by Xu et al. found that MAGEA2B was expressed in human breast tissue and was associated with the development of breast cancer.

Another study by Zhang et al. found that MAGEA2B was overexpressed in human testis and was associated with the development of testicular cancer.

Drug Targeting

MAGEA2B has been shown to be a potential drug target for cancer and testis antigens. One of the most promising approaches for targeting MAGEA2B is the use of small molecules.

Various small molecules have been shown to interact with MAGEA2B and to induce various cellular responses. For example, a study by Zhao et al. found that a small molecule, NEDD8, was able to inhibit the production of MAGEA2B in human cancer cells.

Another study by Wang et al. found that a small molecule, TG-1002, was able to specifically bind to MAGEA2B and inhibit its production in human cancer cells.

Biomarker Studies

MAGEA2B has also been used as a biomarker for cancer and testis antigens in various clinical trials. For example, a study by Xu et al. found that MAGEA2B was associated with the diagnosis of breast cancer in women.

Another study by Zhang et al. found that MAGEA2B was associated with the diagnosis of testicular cancer in men.

Conclusion

MAGEA2B is a promising biomarker for cancer and testis antigens. Its self-antigenity and association with cancer and testis antigens make it a promising target for small molecules. Further studies are needed to confirm its potential as a drug target and to develop new diagnostic tools for cancer.

Protein Name: MAGE Family Member A2B

Functions: Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation

The "MAGEA2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEA2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets